eazopep 20 20 mg / capsule
new medical centre trading united arab emirates - 14's (7's blisters x 2) - capsule - 20 mg / capsule - gastrointestinal system-ulcer-healing
eazopep 40 40 mg / capsule
new medical centre trading united arab emirates - 14's (7's blisters x 2) - capsule - 40 mg / capsule - gastrointestinal system-ulcer-healing
eazopep 20
14's (7's blisters x 2) -
eazopep 40
14's (7's blisters x 2) -
tazopip 4 g/0.5 g piperacillin (as sodium) 4 g and tazobactam (as sodium) 0.5 g powder for injection vial
alphapharm pty ltd - piperacillin sodium, quantity: 4.2 g (equivalent: piperacillin, qty 4 g); tazobactam sodium, quantity: 0.54 g (equivalent: tazobactam, qty 0.5 g) - injection, powder for - excipient ingredients: - tazopip is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta -lactamase producing organisms in the conditions as listed: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated). 3.intra- abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections. children under the age of 12 years: in hospitalised children aged 2 to 12 years, tazopip is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. while tazopip is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta -lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine
tazopip 2 g/0.25 g piperacillin (as sodium) 2 g and tazobactam (as sodium) 0.25 g powder for injection vial
alphapharm pty ltd - piperacillin sodium, quantity: 2.1 g (equivalent: piperacillin, qty 2 g); tazobactam sodium, quantity: 0.27 g (equivalent: tazobactam, qty 0.25 g) - injection, powder for - excipient ingredients: - tazopip is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta -lactamase producing organisms in the conditions as listed: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated). 3.intra- abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections. children under the age of 12 years: in hospitalised children aged 2 to 12 years, tazopip is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. while tazopip is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta -lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine
tazopip
aspen pharmacare australia pty ltd - tazobactam sodium; piperacillin sodium -
tazopipe combination for i.v. drip infusion bag 2.25"dsep" (タゾピペ配合点滴静注用バッグ2.25「dsep」)
daiichi sankyo espha co., ltd. - tazobactam; piperacillin hydrate - injection - it is usually used to treat sepsis, pneumonia, pyelonephritis, complicated cystitis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis or pyrogenic neutropenia.
tazopipe combination for i.v. drip infusion bag 4.5"dsep" (タゾピペ配合点滴静注用バッグ4.5「dsep」)
daiichi sankyo espha co., ltd. - tazobactam; piperacillin hydrate - injection - it is usually used to treat sepsis, pneumonia, pyelonephritis, complicated cystitis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis or pyrogenic neutropenia.
tazopipe combination for i.v. injection 2.25 "dsep" (タゾピペ配合静注用2.25「dsep」)
daiichi sankyo espha co., ltd. - tazobactam; piperacillin hydrate - injection - it is usually used to treat sepsis, pneumonia, pyelonephritis, complicated cystitis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis or pyrogenic neutropenia.